EFTR Stock Overview
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer.
+ 2 more risks
Notes are coming soon
eFFECTOR Therapeutics, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.48|
|52 Week High||US$5.97|
|52 Week Low||US$0.36|
|1 Month Change||14.69%|
|3 Month Change||-22.27%|
|1 Year Change||-91.43%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-95.16%|
Recent News & Updates
|EFTR||US Biotechs||US Market|
Return vs Industry: EFTR underperformed the US Biotechs industry which returned 10.5% over the past year.
Return vs Market: EFTR underperformed the US Market which returned -8.5% over the past year.
|EFTR Average Weekly Movement||19.3%|
|Biotechs Industry Average Movement||12.2%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||17.3%|
|10% least volatile stocks in US Market||2.9%|
Stable Share Price: EFTR is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 19% a week.
Volatility Over Time: EFTR's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 2clinical trial to treat patients with solid tumors.
eFFECTOR Therapeutics, Inc. Fundamentals Summary
|EFTR fundamental statistics|
Is EFTR overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|EFTR income statement (TTM)|
|Cost of Revenue||US$23.06m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||0.13|
|Net Profit Margin||176.98%|
How did EFTR perform over the long term?See historical performance and comparison